Company

Letter

  • Home
  • Company
  • Letter
Company
Letter
Creating value
for shareholders
Through the Letter, we share performance, strategic direction, and long-term goals.

Greetings! I am Wonsuk Lee, CEO of Daehan Nupharm.

Thank you for visiting our website and for always showing great interest and support.

Today, we live in a time of change faster than ever before. Technology is advancing and industries are constantly evolving, with the roles and responsibilities of companies being redefined accordingly. Amid these changes, we seek to keep one value at our core. That value is “warmth that puts people first.”

Daehan Nupharm’s management philosophy does not stop at simple growth or pursuit of profit. We cherish warm human connections like body heat between people and aim to realize sustainable and meaningful innovation based on mutual respect and care. This is the starting point and ultimate direction of all our businesses.

Thus, all our management activities begin with deep recognition of responsibility to society, to the environment, and to future generations. From ecofriendly production and distribution and transparent, responsible management to mutual growth with partners and local communities, we constantly strive to realize sustainable values in every business process.

We believe that the innovation we pursue should not only be scientific advancement but also a means of making human life healthier and richer, ultimately building a better society. We will choose the path of communication, empathy, and moving forward together with customers, partners, employees, and society as a whole.

Going forward, Daehan Nupharm will continuously create meaningful value and innovation centered on respect for people and social responsibility under its mission of being “a company that shares warmth.” We will continue steady but genuine steps so that the company’s growth leads directly to society’s growth. With your continued interest and support, we will prepare for the future with even greater responsibility and advance toward a better world. Thank you.
 

September 15, 2025 

CEO, Daehan Nupharm

Wonsuk Lee

Greetings! Respected shareholders of Daehan Nupharm,

Despite the difficult environment in 2024 such as drug price reductions, stricter regulations, and rising costs, we achieved excellent results. We recorded sales of 202.1 billion KRW, operating profit of 18.6 billion KRW, and net profit of 15.4 billion KRW. For 2025, we are pushing forward with strategies by setting strategic indicators and goals for each business division to ensure sales growth. 

With your continued interest, Daehan Nupharm promises that 2025 will be a year of achieving goals alongside new challenges, and I would like to share today’s key priorities.

First are safety and quality. Safety and quality complement each other. In a safe working environment, high-quality pharmaceuticals can be produced, and high-quality medicines play a crucial role in ensuring user safety and patient health. This goes beyond production activities alone and represents a core value for the company’s long-term growth and sustainability. In particular, since safety and quality are central pillars of ESG management, we will manage and improve them thoroughly to secure sustainable growth drivers in the long term.

Second is the advancement of production facilities. The Hyangnam Project is progressing smoothly, having broken ground last May. The new plant is scheduled to start operations in 2027, and we will continue to invest in related research and development.

Third is strengthening research and development. Our Pangyo Central Research Institute and Bio Research Institute are continuously pursuing the expansion of pipelines, creation of opportunities for new research materials, licensing-in, and joint research on pharmaceuticals, veterinary medicines, and health functional foods, thereby enabling synergies across divisions.

The year 2025 marks the meaningful 40th anniversary of Daehan Nupharm. We have written a history full of challenges and achievements over the past 40 years, and we will build a new future that surpasses this legacy for the next 40 years. 

To this end, we will pursue continuous change—constructing new plants, strengthening R&D, and introducing new IT systems—while constantly challenging ourselves to grow into a globally recognized pharmaceutical and bio company

We ask for your continued interest and support.

I sincerely thank all shareholders who took the time to attend this general meeting despite your busy schedules, and I wish your health, peace, and happiness.

 

Mar. 20, 2025 

Daehan Nupharm Co., Ltd.

CEO Wonsuk Lee

Greetings! Respected shareholders of Daehan Nupharm,

In 2023, our sales grew 3% year-on-year to 204.2 billion KRW, with operating profit of 18.8 billion KRW and net profit of 12.5 billion KRW. This year as well, we are pursuing business by setting goals and strategic indicators by division to ensure continuous sales growth. 

With your support, we promise that 2024 will also be a year of achieving goals alongside new challenges.

In April last year, we completed the first phase of the Hyangnam Project—the construction of the research building—and we are pushing ahead with phase two: the new plant construction. We are now in the final stages of design, and we plan to break ground in May. Once plant construction and validation are completed, full production will begin in 2027. When the new plant is completed, our company will have Korea’s leading lyophilized injectable production line.

Daehan Nupharm will not only build new plants and upgrade production systems but also continue product R&D to ensure healthier lives for patients and animals. We ask for your continued interest and support. 

I sincerely thank all shareholders who attended this meeting despite your busy schedules, and I wish you good health and abundant happiness.

 

Mar. 18, 2024

Daehan Nupharm Co., Ltd.

CEO Wonsuk Lee


Greetings! Respected shareholders of Daehan Nupharm,

In 2022, we achieved our goals including the first successful clinical trial of an improved new drug and the hosting of a symposium thanks to our employees’ responsibility and passion. Sales grew 19% year-onyear to 198 billion KRW, with operating profit of 27.6 billion KRW and net profit of 24.3 billion KRW. We are pursuing business this year with strategic goals to enable further growth.

With your interest, Daehan Nupharm promises that 2023 will be a year of achieving goals alongside new challenges, and I would like to announce new priorities here today.

First is the advancement of production facilities. Expansion of the research support building—the first step of the Hyangnam Project—is in progress, with the remodeling of the solid dosage line to be completed in the first half of this year. Phase two will be construction of the pharmaceutical warehouse and veterinary medicine production building, and phase three will be construction of the injectable plant.

The company will make strategic plans to push the project forward as quickly as possible. The Hyangnam Project will serve as a cornerstone for the stable production of our high-quality products and our growth into a global R&D-driven pharmaceutical and bio company.

Second is strengthening internal capabilities and systems.
We must strengthen not only hardware such as construction and facilities but also software. Stricter GMP regulations mean that simply performing DI or adopting LIMS is insufficient. Alongside workforce expansion, we will focus on strengthening internal capabilities through training.

Third, we will invest in research and development. The re-evaluation of listed drugs beginning July is expected to bring seismic changes to the industry.
This means that pharmaceutical companies that do not engage in R&D will find it difficult to survive. Our Pangyo Central Research Institute and Bio Research Institute are continuously expanding pipelines, while the newly established Future Business Division will create opportunities for new research materials, licensing-in, and joint research on pharmaceuticals, veterinary medicine, and health functional foods, fostering inter-divisional synergies. 

Although high interest rates and inflation are expected to persist this year due to the global economic crisis, Daehan Nupharm achieved remarkable growth amidst such challenges. We will continue to evolve into a globally recognized pharmaceutical and bio company through relentless determination and goal achievement. 

We ask for your continued interest and support.

Finally, I sincerely thank all shareholders who attended this meeting despite the pandemic and wish your health, peace, and happiness. 
 

Mar. 21, 2023

Daehan Nupharm Co., Ltd.

CEO Wonsuk Lee

Article 1 (Purpose)
These Terms and Conditions are intended to define the terms of use, rights, obligations, and responsibilities between Daehan Nupharm Co., Ltd. (hereinafter the “Company”) and users regarding all websites operated by the Company (hereinafter the “Site”) and any online contents provided through the Site (hereinafter the “Contents”).
Article 2 (Effect and Amendment of the Terms)
1. These Terms shall apply to all users (including job applicants) who wish to use the Site and its Contents, as stated at the bottom of the Site.
2. Users who access the Site or register by giving consent shall be deemed to have agreed to these Terms.
3. The Company may amend these Terms to the extent that such changes do not violate relevant laws including the Act on the Regulation of Terms and Conditions. Any amended Terms shall take effect upon notice through the Site.
4. Continued use of the Site or the Contents after such notice shall be deemed acceptance of the revised Terms.
Article 3 (Matters Not Specified in the Terms)
Any matters not specified herein shall be governed by relevant laws and regulations.
Article 4 (Obligations)
Obligations of the Company
The Site shall maintain the confidentiality of users’ personal information and use it solely for purposes within the Site, such as improving and operating services or providing new information. It shall not be transferred to any third party for any other purpose. (However, exceptions shall be made where disclosure is legally required—for example, upon a lawful request by investigative authorities or the Korea Communications Standards Commission.)

Obligations of Users and Job Applicants
1. Users must comply with these Terms, applicable laws, and all notices posted on the Site.
2. Users may not engage in profit-seeking activities using the information or Contents without prior consent from the Company. That is, information or Contents obtained from the Site may not be reproduced, modified, published, or broadcast without the Company’s prior approval.
3. Users must not alter or distribute information or Contents provided by the Site in any manner that violates public order or decency
4. Users must not infringe any intellectual property rights, including copyrights, without the Company’s consent, nor harm the reputation of the Site or third parties, or interfere with their business.
Article 5 (Service Availability)
The Site shall, in principle, be available year-round without interruption, except in cases of business or technical difficulties or other unavoidable circumstances. However, the Company may partially or fully restrict service when necessary—such as for maintenance, system failure, or service overload caused by force majeure.
Article 6 (Provision, Restriction, and Suspension of Information)
1. The administrator may, in the course of operating the Site, provide various information through channels other than the Site itself.
2. The Company may restrict or suspend service when it becomes impossible to continue providing it.
Article 7 (Disclaimer)
1. The Company shall not be liable for any failure to operate the Site or provide Contents due to policy changes, special circumstances, or force majeure.
2. The Company shall not be liable for any service interruptions or restrictions arising from causes attributable to the user.
3. The Company shall not be responsible for information posted by users; all responsibility lies with the user.
4. The Company shall not be liable for any disputes or issues between users and third parties arising through the Site.
5. The Company shall not be liable for any damages caused by the intentional acts or negligence of users or visitors arising from the Site or its Contents.
6. The Company shall not be responsible for users’ failure to gain expected benefits from the service, or for any damages resulting from their choice or use of service materials.
Article 8 (Compensation for Damages)
The Company shall not be liable for any damages incurred by users in connection with the use of the Site or its Contents.
Article 9 (Governing Law and Jurisdiction)
Any disputes or lawsuits arising between the Company and users in relation to the use of the Site and its Contents shall be subject to the jurisdiction of the court having authority over the location of the Company’s head office, and the governing law shall be the laws of the Republic of Korea.
Daehan Nupharm Co., Ltd. (hereinafter referred to as the “Company”) values customers’ personal information and complies with the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc.
Through this Privacy Policy, the Company informs you of how and for what purposes your personal information is used,
and what measures are being taken to protect your personal data.
In the event of any amendments to this Privacy Policy, the Company will notify users through website announcements (hereinafter referred to as the “Site”) or individual notices.
This policy has been effective since January 1, 2014.
Items of Personal Information Collected
The Company collects the following personal information for purposes such as job applications, consultations, inquiries, and service requests.

Collected items: name, date of birth, gender, phone number (mobile/landline), address, email, photo, educational background, occupation, career details, company name, department, position, period of employment, educational history, career history, salary, job description, projects undertaken, detailed work tasks, major achievements, reason for resignation, qualifications, family information, self-introduction, veteran status, disability status, and any personal information submitted by the user for recruitment purposes. Additionally, during service use or business processing, the following information may be automatically generated and collected:
Type of browser and operating system, visit records (IP address, access time), and cookies.
Method of collection: through the Site (general inquiries, product inquiries, partnership proposals, recruitment).
Purpose of Collecting and Using Personal Information
The Company utilizes the collected personal information for the following purposes:
Responding to various inquiries.
User management and handling of complaints or civil petitions.
Evaluation and processing of recruitment applications.
Retention and Use Period of Personal Information
In principle, personal information is destroyed without delay once the purpose of collection and use has been fulfilled.
However, if retention is required under relevant laws and regulations, the Company may retain user information for a specific period as prescribed by such laws.
Items retained: Personal information items specified above.
Legal basis for retention: Consumer protection and data management.
Retention period: 3 years.
Records related to consumer complaints or dispute resolution: 3 years (in accordance with the Act on the Consumer Protection in Electronic Commerce, etc.)
Procedures and Methods of Personal Information Destruction
In principle, the Company promptly destroys personal information once the purpose of collection and use has been achieved. The procedures and methods of destruction are as follows:
Destruction procedures: Information entered by users for purposes such as membership or application submission is transferred to a separate database (or stored separately in paper form) after the purpose has been achieved. It is retained for a certain period in accordance with internal policies and relevant laws (refer to retention and use period), and then destroyed. Personal information transferred to a separate database is not used for any purpose other than as required by law.
Destruction method: The data is deleted using a database deletion method.
Provision of Personal Information
The Company does not, in principle,
When users have given prior consent.
When required by law or when an investigative agency requests such information in accordance with legally prescribed procedures.
Entrustment of Collected Personal Information
The Company does not entrust users’ personal information to external companies without prior consent.
Should such entrustment become necessary in the future, the Company will notify users of the entrusted party and the scope of the entrusted tasks, and obtain prior consent when required.
Rights of Users and Legal Representatives, and Exercise Thereof
Users may, at any time, view or modify their registered personal information and may also request withdrawal of membership.
If you contact the Personal Information Manager in writing, by phone, or via e-mail, the Company will take prompt action.
When you request correction of an error in your personal information, the Company will not use or provide such information until the correction has been completed.
If incorrect information has already been provided to a third party, the Company will notify the third party of the correction without delay so that it may be applied.
Personal information that has been canceled or deleted at the user’s request is handled according to the “Retention and Use Period of Personal Information” policy and will not be viewed or used for any other purpose.
For users under the age of 14, their legal representative has the right to access or correct the child’s personal information and to withdraw consent to its collection and use.
Use of Cookies
Purpose of Using Cookies
Cookies are used to prevent duplicate display of pop-up notifications.
Installation, Operation, and Rejection of Cookies
Users have the option to accept or reject the installation of cookies. Accordingly, users can set their web browser options to allow all cookies, to confirm each time a cookie is stored, or to reject all cookies.
By adjusting the settings of the web browser in use, users may allow all cookies, be prompted to confirm each time a cookie is saved, or refuse the storage of all cookies.
Example of setting method (for Internet Explorer): Tools at the top of the web browser → Internet Options → Privacy tab.
Personal Information Complaint and Inquiry Service
To protect customers’ personal information and handle related complaints, the Company designates the following department and Personal Information Manager
Customer Service Department: IT Team, Management Information Division
Personal Information Manager: Park Kangwon
Phone No.: +82-31-778-2626
Email: webmaster@dhnp.co.kr

You may contact the Personal Information Manager or the responsible department regarding any inquiries or complaints related to personal information protection arising from the use of the Company’s services.
The Company will provide prompt and adequate responses to your inquiries.
For further reports or consultations concerning personal data infringement, please contact the following organizations:

1. Personal Information Infringement Report Center (www.1336.or.kr/ No area code 118)
2. Korea Internet & Security Agency, Privacy Mark Certification Committee (www.eprivacy.or.kr/+82-2-580-0533–4)
3. Supreme Prosecutors’ Office Cyber Crime Investigation Center (http://icic.sppo.go.kr/+82-2-3480-3600)
4. National Police Agency Cyber Terror Response Center (www.ctrc.go.kr/+82-2-392-0330)